ATE452651T1 - Orale impfstoff-zusammensetzung - Google Patents

Orale impfstoff-zusammensetzung

Info

Publication number
ATE452651T1
ATE452651T1 AT99940438T AT99940438T ATE452651T1 AT E452651 T1 ATE452651 T1 AT E452651T1 AT 99940438 T AT99940438 T AT 99940438T AT 99940438 T AT99940438 T AT 99940438T AT E452651 T1 ATE452651 T1 AT E452651T1
Authority
AT
Austria
Prior art keywords
microparticles
oral vaccine
vaccine formulations
less
vaccine composition
Prior art date
Application number
AT99940438T
Other languages
German (de)
English (en)
Inventor
David Brayden
Original Assignee
Merrion Res Iii Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Res Iii Ltd filed Critical Merrion Res Iii Ltd
Application granted granted Critical
Publication of ATE452651T1 publication Critical patent/ATE452651T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99940438T 1998-09-01 1999-08-31 Orale impfstoff-zusammensetzung ATE452651T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9875998P 1998-09-01 1998-09-01
PCT/IE1999/000086 WO2000012124A1 (en) 1998-09-01 1999-08-31 Oral vaccine compositions

Publications (1)

Publication Number Publication Date
ATE452651T1 true ATE452651T1 (de) 2010-01-15

Family

ID=22270760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940438T ATE452651T1 (de) 1998-09-01 1999-08-31 Orale impfstoff-zusammensetzung

Country Status (7)

Country Link
EP (2) EP2168593A1 (enExample)
JP (1) JP4601823B2 (enExample)
AT (1) ATE452651T1 (enExample)
AU (1) AU5441199A (enExample)
CA (1) CA2341352C (enExample)
DE (1) DE69941848D1 (enExample)
WO (1) WO2000012124A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
EP1443912B1 (en) * 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
DE60319073T2 (de) * 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
FR2857592B1 (fr) * 2003-07-18 2006-02-24 Sod Conseils Rech Applic Nouveau procede de preparation de microparticules
JP5050144B2 (ja) * 2005-04-20 2012-10-17 満 明石 アジュバントとしてのポリアミノ酸
JP4621218B2 (ja) * 2007-02-09 2011-01-26 有限会社バイオ研 Ｔｈ１誘導剤及びその製造方法
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
ATE129159T1 (de) * 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
AU667003B2 (en) 1993-01-08 1996-02-29 Csl Limited Vaccine preparations
CA2172507C (en) 1993-10-22 2008-12-02 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
CA2156718A1 (en) 1993-12-23 1995-06-29 Bruno Gander Immunological response potentiation process
JP3747077B2 (ja) * 1994-04-28 2006-02-22 武田薬品工業株式会社 百日咳菌由来感染防御成分の分離取得方法
CA2207961A1 (en) * 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines

Also Published As

Publication number Publication date
WO2000012124A1 (en) 2000-03-09
CA2341352C (en) 2013-01-08
DE69941848D1 (de) 2010-02-04
CA2341352A1 (en) 2000-03-09
JP2002523470A (ja) 2002-07-30
AU5441199A (en) 2000-03-21
JP4601823B2 (ja) 2010-12-22
EP2168593A1 (en) 2010-03-31
EP1107782B1 (en) 2009-12-23
EP1107782A1 (en) 2001-06-20

Similar Documents

Publication Publication Date Title
DE69941848D1 (de) Orale impfstoff-zusammensetzung
FI935396A7 (fi) Uudet nanopartikkelien muodossa olevat, veren röntgenvarjoainekoostumukset, joissa on suuren molekyylipainon pinta-aktiivista ainetta
NO952077D0 (no) Sammensetning bestående av en dendrimer og en aktiv substans okkludert deri
BR0005139A (pt) Emulsão cosmética ou dermatológica comportando pelo menos um sistema fotoprotetor, composição cosmética e/ou dermatológica, utilizacao da emulsão e utilização de polìmero associativo
NO20002741L (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
TR27536A (tr) Plak önleyici, dis tasi önleyici maddeler iceren agiz bilesimleri.
CA2320182A1 (en) Compositions containing organic compounds
CA2096529A1 (en) Recombinant avirulent salmonella antifertility vaccines
CA2266403A1 (en) Stable photoprotective compositions
FI885109A0 (fi) Foerfarande foer solidifikation och inkapsling med anvaendning av kaern-skalpolymerpartiklar.
NO913136D0 (no) Preparat for oeyedraaper.
CA2177668A1 (en) Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
AU5973390A (en) Encapsulation method, microelectronic devices made therefrom, and heat curable compositions
JP2002523471A5 (enExample)
DK0904063T3 (da) Fremgangsmåde til fremstilling af mikropartikler
IT1283325B1 (it) Imballo per confezioni singole, nonche' procedimento e dispositivo per produrlo
JP2002523470A5 (enExample)
GB2336592B (en) Polymer for photoresist,photoresist composition containing the same,and preparation method thereof
PT792165E (pt) Composicoes imunogenicas
TW223648B (en) Vinyloxygruppen aufweisende siloxancopolymere, deren herstellung undverwendung (2)
EP0852246A3 (en) Aromatic polyamide and fullerene containing compositions, moulded articles therefrom
CA2470622A1 (en) Sunscreen composition comprising chlorphenesin
IT9048407A0 (it) Procedimento di regolazione antibloccaggio e sistema antibloccaggio per la esecuzione del procedimento, in particolare per veicoli da altavelocita'.
EP0435788A3 (en) Ma-pvdc formulations, films and structures which maintain high barrier properties after retorting

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties